Concord Medical Co., Ltd. (6518) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Concord Medical Co., Ltd. stock TWD 34.36, price TWD 30.00, upside +14.5%, quality 71 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range 9.75 TWD – 52.10 TWD · fair‑value band 25.77 TWD – 43.38 TWD · the 30.00 TWD price screens below the 34.36 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow Concord Medical Co. in your weekly email
Every Wednesday you see whether Concord Medical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Concord Medical Co., Ltd. provides hospital management support services primarily in Taiwan.
Show moreShow less
The company offers medical management services that include medical training and nursing staffing and assisting on medical management; and procurement services for instruments and equipment, drugs, medical materials and consumables, testing equipment, and reagents and consumables, as well as develops its own brand for medical aesthetic skincare products, health foods, and topical Chinese medicine products.
It is also involved in the medical equipment planning and sales; and medical equipment leasing activities. The company was founded in 2009 and is headquartered in New Taipei City, Taiwan.
Stock analysis
Concord Medical Co., Ltd. (6518) currently trades at 30.00 TWD, while our model-based Fair Value estimate is 34.36 TWD, implying the stock looks roughly 13% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 61.22 TWD per share, and 16 of the 26 models we run sit above the 30.00 TWD price.
Bear case: the Earnings-Based group reads lowest at 17.51 TWD, and 10 of the 26 models stay below the price. Data coverage for this calculation is low.
Scenario range: 25.77 TWD (bear) to 43.38 TWD (bull), the price of 30.00 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 71/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Concord Medical Co., Ltd. reported revenue of 964M TWD in FY2025 versus 739M TWD in FY2021, a compound +6.9%/yr. Reported net income was 67.4M TWD in FY2025, compounding +18.3%/yr from FY2021.
Key figures
Market cap 1,000M TWD (≈ $30.5M) Micro · P/E ratio 11.8 · P/S ratio 0.95 · EPS (TTM) 2.55 TWD · Dividend yield 5.0% · Net margin 8.3% · Return on equity 12.0% · Return on assets (EBIT) 5.0% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 45 out of 100 (low confidence).
What moves the price
The share trades about 42% below its 52-week high and 24% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at 15%, 6518 screens cheaper than that median.
Fair Value models
Bear25.77 TWDFair Value 34.36 TWDBull43.38 TWD
Price 30.00 TWD · Upside +14.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.9004 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.65/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+8.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.6%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.0%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+12.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+7.9%
Dividend (yield on the price)5.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 8%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−14.1%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about −15.4% a year for the price.
Compare Concord Medical Co., Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks
Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score71 · Top 25%
Fair Value upside+16.7% · Above median
Profitability
Return on equity (12 months)12.0% · Above median
Return on assets5.5% · Above median
Net margin (12 months)8.3% · Below median
Operating margin (12 months)6.1% · Below median
Growth and dividend
Revenue growth (quarter YoY)16.5% · Above median
Dividend yield (12 months)5.0% · Top 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Concord Medical Co., Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/6518
Frequently asked questions
Is Concord Medical Co., Ltd. (6518) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of 34.36 TWD versus a price of 30.00 TWD, about +15% upside (undervalued).
What is the fair value of 6518?
Our model-based fair value for Concord Medical Co., Ltd. is 34.36 TWD (as of Nov 4, 2026), built from audited fundamentals. The current price: 30.00 TWD.
What is the quality score of 6518?
Concord Medical Co., Ltd. has a Quality Score of 71/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Concord Medical Co., Ltd. (6518)?
Our model-based price target is the fair value of 34.36 TWD (as of Nov 4, 2026) from 26 valuation models. Cautious scenario 25.77 TWD, optimistic scenario 43.38 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Concord Medical Co., Ltd. stock forecast for 2026?
Our models put fair value at 34.36 TWD, about +15% upside versus a price of 30.00 TWD (undervalued). Cautious scenario 25.77 TWD, optimistic scenario 43.38 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Concord Medical Co., Ltd. (6518)?
Concord Medical Co., Ltd. reported trailing-twelve-month revenue of about 1.0B TWD (latest available figure, as of Nov 4, 2026).
Does Concord Medical Co., Ltd. pay a dividend?
Concord Medical Co., Ltd. currently shows a dividend yield of 5.00% relative to its recent price (as of Nov 4, 2026).
How much is the dividend of Concord Medical Co., Ltd. (6518) and when is the ex-dividend date?
Concord Medical Co., Ltd. pays a dividend of 1.50 TWD per share a year, a dividend yield of 5.0%. The last ex-dividend date was Apr 10, 2026. A dividend has been paid every year since 2019. The payout ratio is 58.8% of earnings. Free cash flow covers the dividend 2.44 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Concord Medical Co., Ltd. (6518)?
For today's price to be fair in a discounted-cash-flow model, Concord Medical Co., Ltd. would have to grow free cash flow by -14.1 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +3.6 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of 6518 use?
Our models discount Concord Medical Co., Ltd. at 9.0 %: a base by market capitalisation (nano), damped by beta 0.31, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Concord Medical Co., Ltd. that is -14.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has Concord Medical Co., Ltd. (6518) delivered so far?
Over the past 5 years revenue at Concord Medical Co., Ltd. grew +3.6 % a year. The price currently implies free-cash-flow growth of -14.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Concord Medical Co., Ltd. (6518) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into Concord Medical Co., Ltd. (-14.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Concord Medical Co., Ltd. (6518)?
The free-cash-flow yield on the price is 12.20 %: that much free cash flow Concord Medical Co., Ltd. produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Concord Medical Co., Ltd. (6518)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Concord Medical Co., Ltd. it is 34.36 TWD per share (as of Nov 4, 2026), against a price of 30.00 TWD. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Concord Medical Co., Ltd. stock overvalued or undervalued in 2026?
As of Nov 4, 2026, 6518 trades below its calculated fair value: price 30.00 TWD, fair value 34.36 TWD, a gap of about +15% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6518?
No. The price is what the market pays today (30.00 TWD); the fair value is what the company's own numbers justify (34.36 TWD). For Concord Medical Co., Ltd. the two are 4.36 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Concord Medical Co., Ltd. worth?
The market values Concord Medical Co., Ltd. at about 1,000M TWD (market capitalisation, as of Nov 4, 2026). Per share that is 30.00 TWD; our models calculate a fair value of 34.36 TWD per share.
What do the bullish and bearish scenarios say about 6518?
Our models span a range for Concord Medical Co., Ltd.: cautious scenario 25.77 TWD, base 34.36 TWD, optimistic 43.38 TWD per share (as of Nov 4, 2026, price 30.00 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6518?
Concord Medical Co., Ltd. trades at a price-to-earnings ratio of 11.8 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 34.36 TWD is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2019 to 2025), reported earnings: 15.5. Other multiples: P/B 1.4, P/S 0.9, EV/EBITDA 7.1.
How solid is the balance sheet of Concord Medical Co., Ltd. (6518)?
Balance-sheet figures for Concord Medical Co., Ltd. (as of Nov 4, 2026): return on equity 12.0%. They feed the Quality Score of 71/100, which measures business quality independently of the share price.
How far is 6518 from its 52-week high?
Concord Medical Co., Ltd. trades at 30.00 TWD, about 42% below its 52-week high of 52.10 TWD and 24% above the low of 24.12 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 34.36 TWD is for.
Which stocks are comparable to Concord Medical Co., Ltd.?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Concord Medical Co., Ltd. stock attractive at the current price?
The data as of Nov 4, 2026: price 30.00 TWD, calculated fair value 34.36 TWD (+15%), Quality Score 71/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6518 calculated?
We run Concord Medical Co., Ltd. through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 34.36 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Concord Medical Co., Ltd. currently trades 13% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Concord Medical Co., Ltd. (6518)?
The closing price on Nov 9, 2026 was 30.00 TWD. Our model-based fair value is 34.36 TWD, about +15% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Concord Medical Co., Ltd. right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Concord Medical Co., Ltd.
How large is the market capitalisation of Concord Medical Co., Ltd. (6518)?
The market capitalisation of Concord Medical Co., Ltd. is 1,000M TWD (≈ $30.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Concord Medical Co., Ltd. (6518)?
The price-to-sales ratio of Concord Medical Co., Ltd. is 0.95 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Concord Medical Co., Ltd. (6518)?
Earnings per share at Concord Medical Co., Ltd. are 2.55 TWD (price ÷ EPS = P/E 11.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Concord Medical Co., Ltd. (6518)?
The dividend yield of Concord Medical Co., Ltd. is 5.0% (payout 58.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Concord Medical Co., Ltd. (6518)?
The net margin of Concord Medical Co., Ltd. is 8.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Concord Medical Co., Ltd. (6518)?
The return on equity (ROE) of Concord Medical Co., Ltd. is 12.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Concord Medical Co., Ltd. (6518)?
On an EBIT basis the return on assets of Concord Medical Co., Ltd. is 5.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Concord Medical Co., Ltd. (6518)?
The operating margin of Concord Medical Co., Ltd. is 6.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Concord Medical Co., Ltd. (6518)?
Revenue at Concord Medical Co., Ltd. is growing +16.5% versus a year earlier (3y avg +2.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Concord Medical Co., Ltd. (6518)?
Earnings per share at Concord Medical Co., Ltd. are growing +62.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Concord Medical Co., Ltd. (6518) carry?
The net debt of Concord Medical Co., Ltd. is 101M TWD (fiscal year 2024, ≈ 0.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Concord Medical Co., Ltd. in the live analysis
One click puts Concord Medical Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026